A phase II trial evaluating the feasibility of adding bevacizumab to standard osteosarcoma therapy

Fariba Navid, Victor M. Santana, Michael Neel, M. Beth McCarville, Barry L. Shulkin, Jianrong Wu, Catherine A. Billups, Shenghua Mao, Vinay M. Daryani, Clinton F. Stewart, Michelle Kunkel, Wendene Smith, Deborah Ward, Alberto S. Pappo, Armita Bahrami, David M. Loeb, Jennifer Reikes Willert, Bhaskar N. Rao, Najat C. Daw

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Increased vascular endothelial growth factor (VEGF) expression in osteosarcoma correlates with a poor outcome. We conducted a phase II trial to evaluate the feasibility and efficacy of combining bevacizumab, a monoclonal antibody against VEGF, with methotrexate, doxorubicin and cisplatin (MAP) in patients with localized osteosarcoma. Eligible patients received two courses of MAP chemotherapy before definitive surgery at week 10. Bevacizumab (15 mg/kg) was administered 3 days before starting chemotherapy then on day 1 of weeks 3 and 5 of chemotherapy. After surgery, patients received MAP for a total of 29 weeks; bevacizumab was added every 2 or 3 weeks on day 1 of chemotherapy at least 5 weeks after surgery. Group sequential monitoring rules were used to monitor for unacceptable bevacizumab-related targeted toxicity (grade 4 hypertension, proteinuria or bleeding, grade 3 or 4 thrombosis/embolism, and grade 2–4 major wound complications). Thirty-one patients (median age 12.8 years) with localized osteosarcoma were enrolled. No unacceptable targeted toxicities were observed except for wound complications (9 minor and 6 major), which occurred in 15 patients; none required removal of prosthetic hardware or amputation. The estimated 4-year event-free survival (EFS) rate and overall survival rate were 57.5 ± 10.0% and 83.4 ± 7.8%, respectively. Eight (28%) of 29 evaluable patients had good histologic response (<5% viable tumor) to preoperative chemotherapy. The addition of bevacizumab to MAP for localized osteosarcoma is feasible but frequent wound complications are encountered. The observed histologic response and EFS do not support further evaluation of bevacizumab in osteosarcoma.

Original languageEnglish (US)
Pages (from-to)1469-1477
Number of pages9
JournalInternational Journal of Cancer
Volume141
Issue number7
DOIs
StatePublished - Oct 1 2017
Externally publishedYes

Fingerprint

Osteosarcoma
Drug Therapy
Vascular Endothelial Growth Factor A
Disease-Free Survival
Wounds and Injuries
Therapeutics
Survival Rate
Embolism and Thrombosis
Amputation
Proteinuria
Methotrexate
Doxorubicin
Cisplatin
Bevacizumab
Monoclonal Antibodies
Hemorrhage
Hypertension
Neoplasms

Keywords

  • bevacizumab
  • chemotherapy
  • osteosarcoma
  • phase II
  • survival
  • wound healing

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Navid, F., Santana, V. M., Neel, M., McCarville, M. B., Shulkin, B. L., Wu, J., ... Daw, N. C. (2017). A phase II trial evaluating the feasibility of adding bevacizumab to standard osteosarcoma therapy. International Journal of Cancer, 141(7), 1469-1477. https://doi.org/10.1002/ijc.30841

A phase II trial evaluating the feasibility of adding bevacizumab to standard osteosarcoma therapy. / Navid, Fariba; Santana, Victor M.; Neel, Michael; McCarville, M. Beth; Shulkin, Barry L.; Wu, Jianrong; Billups, Catherine A.; Mao, Shenghua; Daryani, Vinay M.; Stewart, Clinton F.; Kunkel, Michelle; Smith, Wendene; Ward, Deborah; Pappo, Alberto S.; Bahrami, Armita; Loeb, David M.; Reikes Willert, Jennifer; Rao, Bhaskar N.; Daw, Najat C.

In: International Journal of Cancer, Vol. 141, No. 7, 01.10.2017, p. 1469-1477.

Research output: Contribution to journalArticle

Navid, F, Santana, VM, Neel, M, McCarville, MB, Shulkin, BL, Wu, J, Billups, CA, Mao, S, Daryani, VM, Stewart, CF, Kunkel, M, Smith, W, Ward, D, Pappo, AS, Bahrami, A, Loeb, DM, Reikes Willert, J, Rao, BN & Daw, NC 2017, 'A phase II trial evaluating the feasibility of adding bevacizumab to standard osteosarcoma therapy', International Journal of Cancer, vol. 141, no. 7, pp. 1469-1477. https://doi.org/10.1002/ijc.30841
Navid, Fariba ; Santana, Victor M. ; Neel, Michael ; McCarville, M. Beth ; Shulkin, Barry L. ; Wu, Jianrong ; Billups, Catherine A. ; Mao, Shenghua ; Daryani, Vinay M. ; Stewart, Clinton F. ; Kunkel, Michelle ; Smith, Wendene ; Ward, Deborah ; Pappo, Alberto S. ; Bahrami, Armita ; Loeb, David M. ; Reikes Willert, Jennifer ; Rao, Bhaskar N. ; Daw, Najat C. / A phase II trial evaluating the feasibility of adding bevacizumab to standard osteosarcoma therapy. In: International Journal of Cancer. 2017 ; Vol. 141, No. 7. pp. 1469-1477.
@article{2d2afff648d5436ebfb34e3aa1369694,
title = "A phase II trial evaluating the feasibility of adding bevacizumab to standard osteosarcoma therapy",
abstract = "Increased vascular endothelial growth factor (VEGF) expression in osteosarcoma correlates with a poor outcome. We conducted a phase II trial to evaluate the feasibility and efficacy of combining bevacizumab, a monoclonal antibody against VEGF, with methotrexate, doxorubicin and cisplatin (MAP) in patients with localized osteosarcoma. Eligible patients received two courses of MAP chemotherapy before definitive surgery at week 10. Bevacizumab (15 mg/kg) was administered 3 days before starting chemotherapy then on day 1 of weeks 3 and 5 of chemotherapy. After surgery, patients received MAP for a total of 29 weeks; bevacizumab was added every 2 or 3 weeks on day 1 of chemotherapy at least 5 weeks after surgery. Group sequential monitoring rules were used to monitor for unacceptable bevacizumab-related targeted toxicity (grade 4 hypertension, proteinuria or bleeding, grade 3 or 4 thrombosis/embolism, and grade 2–4 major wound complications). Thirty-one patients (median age 12.8 years) with localized osteosarcoma were enrolled. No unacceptable targeted toxicities were observed except for wound complications (9 minor and 6 major), which occurred in 15 patients; none required removal of prosthetic hardware or amputation. The estimated 4-year event-free survival (EFS) rate and overall survival rate were 57.5 ± 10.0{\%} and 83.4 ± 7.8{\%}, respectively. Eight (28{\%}) of 29 evaluable patients had good histologic response (<5{\%} viable tumor) to preoperative chemotherapy. The addition of bevacizumab to MAP for localized osteosarcoma is feasible but frequent wound complications are encountered. The observed histologic response and EFS do not support further evaluation of bevacizumab in osteosarcoma.",
keywords = "bevacizumab, chemotherapy, osteosarcoma, phase II, survival, wound healing",
author = "Fariba Navid and Santana, {Victor M.} and Michael Neel and McCarville, {M. Beth} and Shulkin, {Barry L.} and Jianrong Wu and Billups, {Catherine A.} and Shenghua Mao and Daryani, {Vinay M.} and Stewart, {Clinton F.} and Michelle Kunkel and Wendene Smith and Deborah Ward and Pappo, {Alberto S.} and Armita Bahrami and Loeb, {David M.} and {Reikes Willert}, Jennifer and Rao, {Bhaskar N.} and Daw, {Najat C.}",
year = "2017",
month = "10",
day = "1",
doi = "10.1002/ijc.30841",
language = "English (US)",
volume = "141",
pages = "1469--1477",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "7",

}

TY - JOUR

T1 - A phase II trial evaluating the feasibility of adding bevacizumab to standard osteosarcoma therapy

AU - Navid, Fariba

AU - Santana, Victor M.

AU - Neel, Michael

AU - McCarville, M. Beth

AU - Shulkin, Barry L.

AU - Wu, Jianrong

AU - Billups, Catherine A.

AU - Mao, Shenghua

AU - Daryani, Vinay M.

AU - Stewart, Clinton F.

AU - Kunkel, Michelle

AU - Smith, Wendene

AU - Ward, Deborah

AU - Pappo, Alberto S.

AU - Bahrami, Armita

AU - Loeb, David M.

AU - Reikes Willert, Jennifer

AU - Rao, Bhaskar N.

AU - Daw, Najat C.

PY - 2017/10/1

Y1 - 2017/10/1

N2 - Increased vascular endothelial growth factor (VEGF) expression in osteosarcoma correlates with a poor outcome. We conducted a phase II trial to evaluate the feasibility and efficacy of combining bevacizumab, a monoclonal antibody against VEGF, with methotrexate, doxorubicin and cisplatin (MAP) in patients with localized osteosarcoma. Eligible patients received two courses of MAP chemotherapy before definitive surgery at week 10. Bevacizumab (15 mg/kg) was administered 3 days before starting chemotherapy then on day 1 of weeks 3 and 5 of chemotherapy. After surgery, patients received MAP for a total of 29 weeks; bevacizumab was added every 2 or 3 weeks on day 1 of chemotherapy at least 5 weeks after surgery. Group sequential monitoring rules were used to monitor for unacceptable bevacizumab-related targeted toxicity (grade 4 hypertension, proteinuria or bleeding, grade 3 or 4 thrombosis/embolism, and grade 2–4 major wound complications). Thirty-one patients (median age 12.8 years) with localized osteosarcoma were enrolled. No unacceptable targeted toxicities were observed except for wound complications (9 minor and 6 major), which occurred in 15 patients; none required removal of prosthetic hardware or amputation. The estimated 4-year event-free survival (EFS) rate and overall survival rate were 57.5 ± 10.0% and 83.4 ± 7.8%, respectively. Eight (28%) of 29 evaluable patients had good histologic response (<5% viable tumor) to preoperative chemotherapy. The addition of bevacizumab to MAP for localized osteosarcoma is feasible but frequent wound complications are encountered. The observed histologic response and EFS do not support further evaluation of bevacizumab in osteosarcoma.

AB - Increased vascular endothelial growth factor (VEGF) expression in osteosarcoma correlates with a poor outcome. We conducted a phase II trial to evaluate the feasibility and efficacy of combining bevacizumab, a monoclonal antibody against VEGF, with methotrexate, doxorubicin and cisplatin (MAP) in patients with localized osteosarcoma. Eligible patients received two courses of MAP chemotherapy before definitive surgery at week 10. Bevacizumab (15 mg/kg) was administered 3 days before starting chemotherapy then on day 1 of weeks 3 and 5 of chemotherapy. After surgery, patients received MAP for a total of 29 weeks; bevacizumab was added every 2 or 3 weeks on day 1 of chemotherapy at least 5 weeks after surgery. Group sequential monitoring rules were used to monitor for unacceptable bevacizumab-related targeted toxicity (grade 4 hypertension, proteinuria or bleeding, grade 3 or 4 thrombosis/embolism, and grade 2–4 major wound complications). Thirty-one patients (median age 12.8 years) with localized osteosarcoma were enrolled. No unacceptable targeted toxicities were observed except for wound complications (9 minor and 6 major), which occurred in 15 patients; none required removal of prosthetic hardware or amputation. The estimated 4-year event-free survival (EFS) rate and overall survival rate were 57.5 ± 10.0% and 83.4 ± 7.8%, respectively. Eight (28%) of 29 evaluable patients had good histologic response (<5% viable tumor) to preoperative chemotherapy. The addition of bevacizumab to MAP for localized osteosarcoma is feasible but frequent wound complications are encountered. The observed histologic response and EFS do not support further evaluation of bevacizumab in osteosarcoma.

KW - bevacizumab

KW - chemotherapy

KW - osteosarcoma

KW - phase II

KW - survival

KW - wound healing

UR - http://www.scopus.com/inward/record.url?scp=85021764824&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021764824&partnerID=8YFLogxK

U2 - 10.1002/ijc.30841

DO - 10.1002/ijc.30841

M3 - Article

VL - 141

SP - 1469

EP - 1477

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 7

ER -